Crystal Structure and Molecular Docking Studies of 1-Ethyl-2′-(furan-2-carbonyl)-1′-(furan-2-yl)-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizin]-2-one

The title compound, 1-ethyl-2′-(furan-2-carbonyl)-1′-(furan-2-yl)-1′,2′,5′,6′,7′,7a′-hexahydrospiro [indoline-3,3′-pyrrolizin]-2-one (1), was synthesized via a one-pot multicomponent 1,3-dipolar cycloaddition reaction and the structure of the compound 1 was determined by IR, 1H NMR, 13C NMR, Mass spectrometry and single crystal X-ray diffraction method. The compound 1 crystallizes in the centrosymmetric monoclinic P21/n space group with unit cellparameters a = 13.9675(10) A, b = 9.1490(6) A, c = 16.6482(14) A, β = 104.529(4)° and a cell volume of 2059.42 A3. The crystal structure shows the formation of two-dimensional (2D) layered structure. Each 2D layer was formed by individual enantiomers of the compound 1. The target molecule was formed diastereoselectively via 1,3-dipolar cycloaddition reaction, which was evidenced from its crystal structure. In silico docking studies were carried out to evaluate anti-mycobacterial, anti-microbial and anti-cancer activities using corresponding proteins by using AutoDock Tools version 1.5.6 and AutoDock version 4.2.5.1 docking program. The compound 1 showed good activity against the proteins of mycobacterium tuberculosis (1V10 = − 8.49 kcal/mol), bacterial (4MIO = − 8.64 kcal/mol) and moderate activity against cancer protein (4L9K = − 3.63 kcal/mol). The title compound, 1-ethyl-2′-(furan-2-carbonyl)-1′-(furan-2-yl)-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizin]-2-one (1), crystallizes in the centrosymmetric monoclinic P21/n space group. The crystal structure shows the formation of two-dimensional (2D) layered structure. The target molecule was formed diastereoselectively via 1,3-dipolar cycloaddition reaction, which was evidenced from its crystal structure. Docking studies reveal that the compound 1 showed good activity against the proteins of mycobacterium tuberculosis (1V10 = − 8.49 kcal/mol), bacterial (4MIO = − 8.64 kcal/mol) and moderate activity against cancer protein (4L9K = − 3.63 kcal/mol).